智通财经网·2025-08-26 09:35Group 1 - Shandong Xinhua Pharmaceutical Co., Ltd.'s wholly-owned subsidiary, Shandong Zibo Xinda Pharmaceutical Co., Ltd., has received the drug registration certificate for Clarithromycin suspension from the National Medical Products Administration [1] - The application for the marketing authorization of Clarithromycin suspension was submitted in December 2023 and accepted, with the registration certificate granted in August 2025 [1] - The approval of Clarithromycin suspension will enhance the company's portfolio of anti-infective drugs and improve its overall competitiveness [2] Group 2 - Clarithromycin is indicated for treating infections caused by pathogens sensitive to it, including upper respiratory infections, lower respiratory infections, skin and soft tissue infections, and acute otitis media [2] - The estimated sales of Clarithromycin in public medical institutions in China for 2024 is approximately RMB 1.123 billion [2]